AVT29 (aflibercept high dose biosimilar)
/ Alvotech, Advanz Pharma, Servier, Teva
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
June 01, 2026
AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema
(clinicaltrialsregister.eu)
- P2/3 | N=172 | Recruiting | Sponsor: Alvotech Swiss AG | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetic Macular Edema • Ophthalmology
May 01, 2026
ALVOEYE-HD: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema
(clinicaltrials.gov)
- P3 | N=256 | Recruiting | Sponsor: Alvotech Swiss AG | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetic Macular Edema • Ophthalmology
April 11, 2026
AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema
(clinicaltrialsregister.eu)
- P2/3 | N=172 | Not yet recruiting | Sponsor: Alvotech Swiss AG | N=102 ➔ 172
Enrollment change • Diabetic Macular Edema • Ophthalmology
March 24, 2026
ALVOEYE-HD: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema
(clinicaltrials.gov)
- P3 | N=256 | Not yet recruiting | Sponsor: Alvotech Swiss AG
New P3 trial • Diabetic Macular Edema • Ophthalmology
March 12, 2026
AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema
(clinicaltrialsregister.eu)
- P2/3 | N=102 | Not yet recruiting | Sponsor: Alvotech Swiss AG
New P2/3 trial • Diabetic Macular Edema • Ophthalmology
March 09, 2026
AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema
(clinicaltrialsregister.eu)
- P2/3 | N=11 | Not yet recruiting | Sponsor: Alvotech Swiss AG
New P2/3 trial • Diabetic Macular Edema • Ophthalmology
1 to 6
Of
6
Go to page
1